• Enliven Therapeutics director Mika K. Derynck sold 158,795 shares on Aug. 4 at a weighted average price of $60.21.
• The sale followed option exercises for the same 158,795 shares at prices ranging from $2.48 to $25.28.
• Derynck’s reported direct common stock holdings fell to zero following the transactions.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Enliven Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001865125-26-000004), on August 06, 2026, and is solely responsible for the information contained therein.